273 related articles for article (PubMed ID: 30545534)
1. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
Chikazawa K; Netsu S; Kuwata T; Konno R
Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
[TBL] [Abstract][Full Text] [Related]
2. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E
Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
5. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab in recurrent ovarian cancer.
Sait Bakir M; Birge O; Karadag C; Ilhan Y; Aykut Tuncer H; Sezgin Göksu S; Simsek T
J BUON; 2021; 26(4):1271-1278. PubMed ID: 34564981
[TBL] [Abstract][Full Text] [Related]
7. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).
Farolfi A; Petrone M; Scarpi E; Gallà V; Greco F; Casanova C; Longo L; Cormio G; Orditura M; Bologna A; Zavallone L; Ventriglia J; Franzese E; Loizzi V; Giardina D; Pigozzi E; Cioffi R; Pignata S; Giorda G; De Giorgi U
Target Oncol; 2018 Aug; 13(4):469-479. PubMed ID: 29948780
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.
Parikh R; Kurosky SK; Udall M; Chang J; Cappelleri JC; Doherty JP; Kaye JA
Int J Gynecol Cancer; 2018 May; 28(4):738-748. PubMed ID: 29538247
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
Liu B; An R; Yu J
J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
[TBL] [Abstract][Full Text] [Related]
12. Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Husain A; Wang Y; Hanker LC; Ojeda B; Anttila M; Breda E; Vuylsteke P; Pujade-Lauraine E
Gynecol Oncol; 2016 Sep; 142(3):465-70. PubMed ID: 27184721
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Sorio R; Roemer-Becuwe C; Hilpert F; Gibbs E; García Y; Kaern J; Huizing M; Witteveen P; Zagouri F; Coeffic D; Lück HJ; González-Martín A; Kristensen G; Levaché CB; Lee CK; Gebski V; Pujade-Lauraine E;
Gynecol Oncol; 2017 Jan; 144(1):65-71. PubMed ID: 27871723
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
Hansen MKG; Smerdel MP; Waldstrøm M; Andersen RF; Adimi P; Jakobsen A; Steffensen KD
Cancer Chemother Pharmacol; 2020 Dec; 86(6):751-759. PubMed ID: 33067703
[TBL] [Abstract][Full Text] [Related]
16. Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer.
Normann MC; Türzer M; Diep LM; Oldenburg J; Gajdzik B; Solheim O; Rud E
J Gynecol Oncol; 2019 Jul; 30(4):e56. PubMed ID: 31074244
[TBL] [Abstract][Full Text] [Related]
17. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
18. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
19. Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
Suminokura J; Miyamoto M; Yoshikawa T; Kouta H; Kikuchi Y; Hada T; Ishibashi H; Ito T; Iwahashi H; Kakimoto S; Suzuki R; Matsuura H; Kishimoto N; Takano M
BMC Cancer; 2022 Feb; 22(1):176. PubMed ID: 35172766
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
Miao Y; Li S; Yan Q; Li B; Feng Y
Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
